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Abstract: Lenalidomide is an amino-substituted derivative of thalidomide with direct antipro-
liferative and cytotoxic effects on the myeloma tumor cell, as well as antiangiogenic activity 
and immunomodulatory effects. Together with the introduction of bortezomib and thalidomide, 
lenalidomide has significantly improved the survival of patients with relapsed and refractory 
myeloma. The most common adverse events associated with lenalidomide include fatigue, skin 
rash, thrombocytopenia, and neutropenia. In addition, when lenalidomide is combined with 
dexamethasone or other conventional cytotoxic agents, there is an increase in the incidence of 
venous thromboembolic events. There is now evidence that continued treatment with lenali-
domide has a significant impact on survival by improving the depth and duration of response. 
This highlights the value of adverse event management and appropriate dose adjustments to 
prevent toxicity, and of allowing continued treatment until disease progression. In this review, 
we will discuss the different lenalidomide-based treatment regimens for patients with relapsed/
refractory myeloma. This is accompanied by recommendations of how to manage and prevent 
adverse events associated with lenalidomide-based therapy.
Keywords: lenalidomide, multiple myeloma, immunomodulatory drugs, relapse treatment, 
refractory disease
Introduction
Lenalidomide and pomalidomide, as more potent derivatives of thalidomide, have 
been found to be less toxic and more active than their parent drug in the treatment of 
multiple myeloma (MM).1–4 Because of the structural similarities between thalido-
mide and its derivative immunomodulatory drugs (IMiDs), these agents have similar 
modes of action with both direct antitumor activity and indirect immunomodulatory 
and antiangiogenic effects (Figure 1). IMiDs directly kill MM cells by the induction 
of cell cycle arrest and caspase-dependent apoptosis.5–7 In addition, we have shown 
that IMiDs target a subpopulation of MM cells with stem cell-like features (ie, side-
population cells).8 Recently, it has been demonstrated that cereblon, the primary target 
for thalidomide teratogenicity,9 is required for the cytotoxic effects of thalidomide, 
lenalidomide, and pomalidomide.10
In addition, lenalidomide also impairs MM cell survival and proliferation through 
interference with the protective properties of bone marrow stromal cells, including the 
down-regulation of adhesion molecules such as VCAM-1 and ICAM-1,11,12 and inhibi-
tion of the production of cytokines like IL-6 and TNF-α.13 Furthermore, IMiDs inhibit 
angiogenesis by downregulation of vascular endothelial growth factor and β−fibroblast 
growth factor14,15 and impair osteoclastogenesis by reducing RANKL levels.16 IMiDs also 
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Figure 1 The proposed mechanisms of action of lenalidomide in multiple myeloma include immune modulation (A); interference with tumor microenvironment interactions 
(B); and direct antitumor effects (C). (A) Immunomodulation by lenalidomide includes T cell co-stimulation, suppression of Tregs, increased production of Th1 cytokines, 
and activation of NK and NKT cells. (B) Lenalidomide mediates disruption of myeloma cell-microenvironment interactions via several mechanisms including antiangiogenesis, 
anti-inflammatory effects, antiosteoclastogenic properties, modulation of cytokine production, and downregulation of adhesion molecules. (C) IMiDs also exert direct effects 
on myeloma cells via cell cycle arrest and induction of apoptosis. 
Abbreviations: T reg, regulatory T cell; BMSCs, bone marrow stromal cells; APC, antigen-presenting cell; NK cells, natural killer cells; NKT cells, natural killer T cells; 
ICAM-1, intercellular adhesion molecule 1; vCAM-1, vascular cell adhesion molecule 1; vEGF, vascular endothelial growth factor; RANKL, receptor activator of nuclear 
factor kappa-B ligand; bFGF, basic fibroblast growth factor; TGF-β, transforming growth factor-β; IGF-1, insulin-like growth factor 1; TNF-α, tumor necrosis factor α; IL-6, 
interleukin-6.
have immunomodulatory effects including stimulation of 
T cell proliferation, increased production of IL-2 and IFNγ,13 
and enhancement of cytotoxic T lymphocyte, natural killer T, 
and natural killer effector cell activity against MM cells.17,18 
Lenalidomide is more potent than thalidomide in both 
stimulating T cell proliferation via the T cell receptor and in 
enhancing IL-2 and IFNγ production. IMiDs also decrease 
the development of regulatory T cells in MM.19 In addition, 
lenalidomide inhibits myeloid cell-mediated inflammatory 
function by decreasing the secretion of IL-6, TNFα, and 
IL-10.20 We have demonstrated that IMiDs induce immune 
effector cell activation by triggering positive costimulatory 
molecule CD28 signaling in T cells,17,21 as well as regulate 
cytokine signaling by downregulating the suppressor of 
cytokine signaling (SOCS)1 in immune effector cells in MM, 
thereby inducing IL-2 and IFNγ production.22
In this review, we will discuss the clinical activity and 
optimal use of lenalidomide and lenalidomide-based combi-
nations in the management of relapsed and refractory MM.
Single-agent lenalidomide  
in relapsed/refractory MM
Single-agent lenalidomide was shown to be effective and 
well tolerated in relapsed/refractory MM patients who had 
received a median of three prior regimens as part of a Phase 
I trial in which the maximum tolerated dose (MTD) was 
found to be 25 mg daily, and 29% of the patients obtained 
at least a partial response (PR).4 Importantly, no significant 
somnolence, constipation, or neuropathy was observed. The 
most common adverse events included fatigue, skin rash, 
thrombocytopenia, and neutropenia, which proved manage-
able with dose-reduction and granulocyte colony stimulating 
factor (G-CSF) support.4 Single-agent lenalidomide did not 
significantly increase the risk of venous thromboembolism 
(VTE).4 Other studies have since confirmed that single-agent 
lenalidomide has a favorable tolerability and promising 
efficacy, even after prior treatment with thalidomide, bort-
ezomib, and/or high-dose melphalan with autologous stem 
cell rescue.23,24
Lenalidomide plus dexamethasone 
in relapsed/refractory MM
In vitro studies demonstrated that dexamethasone enhances 
the anti-MM effects of lenalidomide.5,6 Based on these pre-
clinical and early phase clinical trial data suggesting that 
response rates can be markedly enhanced by the addition of 
dexamethasone, two randomized Phase III trials (MM-009 
and MM-010) compared lenalidomide (25 mg on days 1–21 
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of a 28-day cycle) plus dexamethasone (40 mg on days 1–4, 
9–12, and 17–20 for the first four cycles, and 40 mg on days 
1–4 thereafter) with placebo plus dexamethasone in relapsed/
refractory MM patients who had received a median of two 
previous therapies (Table 1). Dimopoloulos et al25 demon-
strated the superior efficacy of lenalidomide-dexamethasone 
compared with placebo plus dexamethasone in terms of higher 
overall response rate (complete response (CR) + PR; 60.2% vs 
24.0%; P , 0.001) and CR rate (15.9% vs 3.4%; P , 0.001). 
The authors also noted that lenalidomide-dexamethasone 
exhibited a longer median time to progression (TTP) (11.3 vs 
4.7 months; P , 0.001) and median overall survival (OS) (not 
reached and 20.6 months; P = 0.03) when compared with 
placebo plus dexamethasone. In the study of Weber et al,26 
comparable results were reported with a superior response rate 
($PR: 61.0% vs 19.9%; P , 0.001), CR rate (14.1% vs 0.6%; 
P , 0.001), median TTP (11.1 vs 4.7 months; P , 0.001), 
and median OS (29.6 vs 20.2 months; P , 0.001) in the 
lenalidomide-dexamethasone group when compared to the 
placebo-dexamethasone group. Adverse events associated 
with lenalidomide therapy were neutropenia, thrombocytope-
nia, and thromboembolic complications in both studies.25,26 
There was a non-significant trend toward increased grade 3 
or 4 infections in lenalidomide recipients.25,26
Pooled analysis of both randomized Phase III trials 
with an extended median follow-up of 48 months demon-
strated a continued prolongation of overall survival for the 
lenalidomide-dexamethasone group (38.0 months) versus the 
dexamethasone single-agent group (31.6 months), despite a 
crossover of 48% of the patients to either lenalidomide or 
lenalidomide plus dexamethasone as subsequent salvage 
therapies.27
Response to lenalidomide plus dexamethasone improved 
over time, with better quality of response associated with 
improved clinical outcomes. Median TTP and OS were lon-
ger in patients who achieved CR/very good partial response 
(VGPR) compared to patients who obtained a PR (TTP: 
27.7 vs 12.0 months; OS: not yet reached vs 44.2 months).28 
San Miguel et al showed that patients who participated in 
MM-009 or MM-010 who achieved PR or better and contin-
ued therapy had an overall survival of 50.9 months, compared 
to 35.0 months in patients who discontinued lenalidomide-
dexamethasone due to adverse events, withdrawal of consent, 
or other reasons.29,30 This suggests that continued treatment 
has a significant impact on survival, possibly by improving 
the depth of response.
Preliminary results from another pooled analysis of both 
Phase III studies showed that patients whose   dexamethasone 
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dose was reduced because of toxicity had a better out-
come compared with patients who continued on high-dose 
dexamethasone.31 In newly diagnosed MM, lenalidomide 
  combined with low-dose dexamethasone was also associated 
with lower toxicity and better overall survival than lenalidomide 
with high-dose dexamethasone;32 this has been widely adopted, 
even in the relapsed/refractory MM setting. An appropriate 
approach to minimize treatment-related toxicity in case of an 
aggressive relapse (eg, with hypercalcemia or renal failure) 
is to start with high-dose dexamethasone for rapid disease 
control, which can be followed by low-dose dexamethasone 
in case of response. Another subanalysis showed that patients 
with progression-free survival (PFS) $12 months who had 
dose reductions of lenalidomide after $12 months had better 
PFS than those who had earlier dose reductions or no dose 
reductions.33 This suggests that it is important to continue full-
dose lenalidomide therapy for at least 12 months in patients 
who tolerate the treatment, and after this time, the dose can be 
reduced without compromising treatment efficacy. Overall, 
these studies highlight the value of adverse event management 
and appropriate dose adjustments to prevent toxicity, thereby 
allowing continued treatment until disease progression.
Efficacy of lenalidomide plus 
dexamethasone and previous treatment
Stadtmauer et al34 showed in a subset analysis of both 
Phase III trials that lenalidomide-dexamethasone was more 
effective in terms of response, TTP, PFS, and OS in patients 
who had one prior therapy when compared to those who had 
two or more earlier therapies, indicating that the greatest 
benefit occurs with early use of lenalidomide-dexamethasone 
in relapsed/refractory MM. Another pooled analysis of all 
patients that participated in these randomized trials showed 
that lenalidomide-dexamethasone was more effective 
than dexamethasone alone in both thalidomide-exposed 
and naïve patients.35 However, higher efficacy in terms of 
overall response rate, TTP, and PFS of the combination 
of lenalidomide-dexamethasone or dexamethasone alone 
was observed in thalidomide-naïve patients compared to 
thalidomide-exposed patients, suggesting some degree of 
cross-resistance between thalidomide and lenalidomide. 
However, patients previously treated with thalidomide had 
significantly more prior lines of therapy compared with 
patients who were thalidomide naïve.35 A French study 
showed similar results with inferior TTP and OS for patients 
that previously progressed on thalidomide.36 In contrast, an 
Italian study showed that response, PFS, and OS were similar 
between thalidomide-resistant and thalidomide-sensitive 
patients.37 A retrospective analysis performed in The Neth-
erlands further showed that response rate was not influenced 
by previous thalidomide or bortezomib treatment.38
In the MM-009 study, the response ($PR) to lenalidomide-
dexamethasone was 68% in bortezomib exposed and 60% 
in bortezomib naïve patients.26 Results from the VISTA 
study also showed that lenalidomide-based therapy is 
equally effective in patients with or without previous 
bortezomib treatment.39 In contrast, a French study high-
lighted that   previous bortezomib exposure was associated 
with   significantly shorter PFS and OS in patients treated 
with lenalidomide-dexamethasone when compared to 
patients with no earlier bortezomib treatment. However, 
patients who received bortezomib had a median of two 
additional lines of therapy, compared to patients who did 
not receive bortezomib.36 Some other studies also suggest 
that prior bortezomib treatment is associated with lower 
efficacy of lenalidomide-dexamethasone.40–42 A retrospective 
single-  center study showed that use of both thalidomide 
and bortezomib prior to lenalidomide-dexamethasone was 
associated with a significant reduction in TTP and OS.41
Regimens with lenalidomide and 
conventional cytotoxic agents
Various other lenalidomide-based regimens have been stud-
ied to further improve the outcome of patients with relapsed/
refractory MM (Table 2). Lenalidomide in combination 
with adriamycin and dexamethasone (RAD) in refractory 
and relapsed MM resulted in a high response rate of 73% 
($PR) including 15% CR and 45% VGPR, with hematologic 
toxicity and infections as the primary side effects.43 Another 
lenalidomide and chemotherapy combination tested in the 
setting of relapsed/refractory MM was lenalidomide com-
bined with pegylated liposomal doxorubicin, vincristine, 
and dexamethasone with an overall response rate ($PR) of 
75% including 29% CR or near CR.44 Myelosuppression, 
neuropathy, muscle cramps, and rash were the most common 
adverse events. Median PFS was 12 months, and median OS 
had not been reached at the time of publication.
Preliminary results from a phase I/II study show that the 
combination of lenalidomide with bendamustine and dex-
amethasone is effective and well tolerated.45 Responses were 
also achieved in patients with prior exposure to lenalidomide. 
A variation on this regimen, bendamustine-lenalidomide 
plus prednisone followed by lenalidomide maintenance was 
evaluated in another Phase I trial. Preliminary results show 
that this combination was well tolerated and active in the 
setting of relapsed/refractory disease.46
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A retrospective study showed that the fully oral combi-
nation of lenalidomide (10 mg) with continuous low-dose 
cyclophosphamide (Endoxan, Baxter 100 mg orally [po]) 
and prednisone (REP) had a remarkably high activity with 
good tolerability in lenalidomide/dexamethasone-refrac-
tory MM ($minimal response (MR): 64%; median PFS: 
12.2 months).47 The efficacy of cyclophosphamide combined 
with lenalidomide and corticosteroids has also been described 
by Morgan et al.48 In a retrospective analysis, they treated 
relapsed lenalidomide-naïve MM patients with the combina-
tion of lenalidomide (25 mg; 21 days, followed by 1 week 
rest), cyclophosphamide (500 mg po; days 1, 8, 15, 21), and 
dexamethasone (40 mg po; days 1–4 and 12–15 of a 28-day 
cycle; RCD regimen) resulting in $MR in 75% of patients.48 
However, progression-free survival of 5.7 months seems 
inferior to REP (12.2 months). The prolonged progression-
free survival of patients treated with the REP regimen may 
be attributed to the continuous exposure of tumor cells to 
antimyeloma agents in this regimen, which possibly prevents 
the emergence of resistant clones.
Based on the promising results from these retrospective 
studies, a prospective Phase I/II study of cyclophosphamide, 
lenalidomide, and dexamethasone was performed in relapsed/
refractory lenalidomide-naïve MM with a median of three 
previous lines of therapy. The MTD was established at lenali-
domide 25 mg on days 1–21, cyclophosphamide 600 mg on 
days 1 and 8, and dexamethasone 20 mg on days 1–4 and 
8–11 of each 28-day cycle. Hematological toxicity could 
be easily managed by dose-reductions. Of all 31 evaluable 
patients, 81% achieved at least PR, including 29% CR.49 
The PFS at 2 years was 56%, and the OS at 30 months was 
80%.49 Another Phase I/II study is currently evaluating the 
combination of lenalidomide plus prednisone and cyclophos-
phamide, and has enrolled 32 lenalidomide-naïve patients.50 
Preliminary data show good tolerability with high efficacy.
Regimens with lenalidomide plus 
proteasome inhibitor
In vitro studies demonstrate that lenalidomide sensitizes 
MM cells to bortezomib-induced apoptosis, which provided 
the rationale for clinical studies evaluating this combination 
(Table 3).6 A Phase I dose-escalation trial evaluated 
lenalidomide plus bortezomib in relapsed and refractory 
MM (median of five prior lines of therapy, including 87% 
of the patients with prior thalidomide, 55% with prior 
bortezomib, and 18% prior lenalidomide). Dexamethasone 
was added if the patient experienced progression after the 
second cycle. The MTD was lenalidomide 15 mg (days 1–14 
of a 21-day cycle) and bortezomib 1.0 mg/m2 (days 1, 4, 
8, 11).51 MR or better was observed in 61% of the patients, 
which included 39% $ PR and 8% CR or near-CR. The most 
common treatment-related grade 3 to 4 toxicities included 
reversible neutropenia, thrombocytopenia, and anemia.51 This 
study was followed by a Phase II trial, which evaluated the 
efficacy of this combination at the MTD in 64 patients with 
relapsed or refractory disease. Preliminary results show an 
impressive overall response rate ($MR) of 78%, including 
64% $ PR and 25% CR plus near-CR.52
Similar results were obtained in a Greek study, which 
demonstrated that the addition of bortezomib to lenalidomide-
dexamethasone was associated with a high response rate of at 
least PR in 63% of patients (median of two previous lines of 
therapy).53 Thalidomide-refractory disease was associated with 
an inferior response rate and survival.53 Another study evaluated 
lenalidomide, bortezomib, and dexamethasone followed by 
lenalidomide-dexamethasone maintenance as treatment of first 
relapse after autologous stem cell transplantation. Preliminary 
data showed a promising response rate ($PR: 71%; $VGPR: 
43%) with a low toxicity profile.54
The addition of pegylated doxorubicin to a modified 
schedule of lenalidomide-bortezomib-dexamethasone was 
evaluated in a Phase II study in relapsed/refractory MM. At 
least PR was achieved in 10 (56%) of 18 patients (median 
of four lines of prior therapy).55
A dose-escalation study is investigating lenalidomide plus 
carfilzomib and dexamethasone in MM patients who have 
received a median of three previous therapies. Preliminary 
results show a response rate ($PR) of 55% across all 
cohorts.56 Responses were also observed in patients who had 
prior therapy with bortezomib or lenalidomide.
Lenalidomide-dexamethasone in combination with 
MLN9708, an oral, potent, reversible proteasome inhibi-
tor, is currently being evaluated in newly diagnosed MM 
(NCT01217957 and NCT01383928). In addition, a phase III 
trial of weekly MLN9708, lenalidomide, and dexametha-
sone in patients with relapsed/refractory MM will soon be 
initiated (NCT01564537).
Regimens with lenalidomide  
and thalidomide
Based on a minimal overlapping side effect profile and 
different mechanisms of action between thalidomide 
(more antiangiogenic activity) and lenalidomide (more 
potent antiproliferative, cytotoxic, and immunomodulatory 
effects) in preclinical studies, the four-drug combination 
of lenalidomide, melphalan, prednisone, and thalidomide 
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was tested in refractory/relapsed lenalidomide-naïve MM 
(Table 3).57 A high response rate was observed, with 75% 
of the 44 patients achieving at least a PR, including 32% 
VGPR and 2% CR. Combining thalidomide with lenalidomide 
seems to increase the hematologic toxicity when compared 
to lenalidomide alone.
Another combination of both IMiDs is lenalidomide, tha-
lidomide, and dexamethasone58 (Table 3). This combination 
was active, with at least PR in 12 out of 13 (92%) evaluable 
patients (median of three prior lines of therapy). Interestingly, 
seven of eight patients (88%) with lenalidomide-refractory 
disease achieved at least a PR, suggesting that thalidomide 
may modulate lenalidomide resistance.
Regimens with lenalidomide  
and new novel agents
mTor inhibitors
In vitro studies demonstrating synergistic antimyeloma activ-
ity between lenalidomide and mTor inhibitors59 provided the 
rationale for testing the combination of lenalidomide and 
temsirolimus in a Phase I trial in relapsed/refractory MM 
patients (n = 21, median of three previous lines of therapy 
including 19% lenalidomide). The maximum tolerated 
dose was lenalidomide 25 mg on days 1–21 of a 28-day 
cycle with 15 mg of temsirolimus weekly. Most common 
adverse events included fatigue, neutropenia, anemia, rash, 
and electrolyte abnormalities. The combination had modest 
activity, with PR in only two patients, and stable disease in 
15 patients.60
Another Phase I study evaluated RAD001 and lenali-
domide in relapsed/refractory MM (28 patients with a 
median of four previous therapies, including 50% prior 
lenalidomide).61 At least PR was obtained in 11% of 
patients.
Histone deacetylase inhibitors
A Phase I trial is evaluating vorinostat, lenalidomide plus 
dexamethasone in patients with relapsed/refractory MM.62 
Patients had received a median of four prior therapies includ-
ing lenalidomide in 45%, thalidomide in 71%, and bort-
ezomib in 65% cases. Fatigue, cytopenias, and diarrhea were 
the most common adverse events. At least PR was achieved 
in 53% of patients, including those previously exposed to 
lenalidomide. Median TTP was 5 months.
The combination of vorinostat, lenalidomide, and dex-
amethasone as a salvage therapy was also evaluated in 29 
lenalidomide-dexamethasone-refractory MM patients with 
a median of four previous lines of therapy.63 At least PR 
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was achieved in 24% of patients, with a median duration of 
response of 4 months. Common toxicities included fatigue, 
myelosuppression, and diarrhea.
Akt inhibitor
Perifosine, an oral Akt inhibitor, was combined with lenali-
domide and dexamethasone in a Phase I trial.64 Patients 
had received a median of two prior lines of treatment, and 
patients refractory to lenalidomide plus dexamethasone were 
excluded. A total of 50% of the patients achieved at least PR, 
and median PFS was 10.8 months.
Lenalidomide and monoclonal 
antibody therapy
The ability of lenalidomide to activate multiple arms of 
the patient’s immune system including enhanced antibody-
dependent cell-mediated cytotoxicity,65,66 coupled with its 
ability to modulate important signaling cascades in MM 
cells, forms the rationale to combine lenalidomide with 
monoclonal antibodies.67 Preliminary results from ongoing 
trials show encouraging results with acceptable toxicity 
for lenalidomide combined with elotuzumab (anti-CS1 
antibody),68,69 lorvotuzumab mertansine (anti-CD56 anti-
body conjugated to DM1),70 and dacetuzumab (anti-CD40 
antibody).71
In vitro studies also demonstrated enhanced cytotoxicity 
of NK cells against MM cells of the combination of NK cell 
activating antibodies and lenalidomide, which also activates 
NK cells.72 Based on these data, a Phase I/II trial is currently 
evaluating lenalidomide combined with 1-7F9, a fully human 
anti-KIR antibody, in relapsed/refractory MM.72
Lenalidomide and cancer vaccines
Suppression of cytotoxic T cells by cytokines such as TGF-
β, recruitment of regulatory T cells, and altered expression 
of immune suppressor molecules on MM cells or immune 
effector cells, contributes to immune evasion in MM. In addi-
tion, the function of dendritic cells and NK cells is severely 
impaired in MM. In a mouse model, a lymphoma vaccine 
in combination with lenalidomide improved survival when 
compared to vaccine or lenalidomide alone. Lenalidomide 
treatment was accompanied with enhanced cellular immu-
nity and ameliorated immune suppression.73 In vitro studies 
showed that lenalidomide also enhanced T cell activation 
in response to stimulation by a dendritic cell/MM fusion 
vaccine.74 A recent clinical study in MM patients showed 
that lenalidomide augmented humoral and cellular responses 
to the polyvalent pneumococcal vaccine, Prevnar (Wyeth 
Pharmaceuticals, Inc, Madison, NJ; Pfizer Inc, New York, 
NY).75 Altogether, these studies indicate that lenalidomide 
has the potential to improve immune dysfunction and can 
serve as an adjuvant for MM vaccines.
Increasing evidence also suggests that IMiDs enhance the 
graft-versus-myeloma effect mediated by donor T cells or 
donor NK cells after allogeneic stem cell transplantation or 
donor lymphocyte infusions.76–80 Unfortunately, use of IMiDs 
in this setting seems also to be associated with increased 
occurrence of graft-versus-host disease.78,79
Cytogenetics
Data from a Canadian study in relapsed or refractory MM 
suggest that lenalidomide-dexamethasone can overcome the 
poor prognosis conferred by del(13q) and t(4;14), but not 
del(17p) (all detected by fluorescence in situ hybridization).40 
However, results from a French multicenter study testing 
lenalidomide-dexamethasone in the relapsed setting showed 
an inferior PFS in patients with del(13q) and t(4;14).36 Also, 
del(1p21) adversely affected the outcome of patients treated 
with lenalidomide-dexamethasone.42
In other lenalidomide-based combinations, del(17p) 
remains a negative prognostic factor, with some combi-
nations overcoming poor prognosis of both t(4;14) and 
del(13q). Response and TTP were identical in patients with 
or without del(13q) or t(4;14) following RAD treatment, 
but del(17p) remained associated with an inferior response 
rate and shortened TTP.43 In addition, when bortezomib 
was added to lenalidomide-dexamethasone, del(17p) was 
still associated with an inferior response rate and survival. 
But bortezomib added to lenalidomide-dexamethasone 
overcame part of the adverse impact conferred by del(13q), 
ampl(1q21), and t(4;14).53 The PFS of patients treated with 
lenalidomide, melphalan, prednisone and thalidomide was 
independent of the presence of del(13q), but was inferior in 
patients with t(4;14).57
Lenalidomide treatment in frail 
or elderly patients with relapsed/
refractory MM
More than half of all new cases of MM occur in patients 
65 years of age or older,81 whereas the proportion of elderly 
relapsed/refractory MM patients enrolled in clinical trials 
decreases with age, and no specific trials are currently avail-
able for unfit elderly MM patients. Furthermore, during the 
last decade, the improvement in survival was more pronounced 
in younger patients,81 which is likely due to patient character-
istics such as lower performance status and comorbidities in 
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the elderly which strongly impact chemotherapy feasibility 
and tolerance. In addition, biologic differences between 
tumors may play a role. This highlights the need for further 
treatment innovations in this population.
Dose adjustments of lenalidomide and other compo-
nents of the salvage regimen, such as dexamethasone, are 
needed to keep patients on therapy and prevent treatment 
discontinuation. Depending on the number of risk factors 
(such as age $ 75 years, frailty, and comorbidities), the 
starting dose of lenalidomide should be 25, 15, or 10 mg on 
days 1–21, and the starting dose of dexamethasone should 
be 40 mg, 20 mg, or 10 mg weekly.82,83 A Phase II trial in 
relapsed/refractory MM patients aged $60 years and/or 
with a creatinine clearance , 60 mL/min showed that lower 
doses of lenalidomide (15 mg) and dexamethasone reduced 
the incidence of hematological toxicities, infections, and 
VTE without compromising efficacy when compared to 
standard dose lenalidomide-dexamethasone (MM-010 and 
MM-009).84 Another lenalidomide-containing salvage regi-
men with proven efficacy accompanied with mild toxicity, 
which may be beneficial to frail MM patients, includes 
dose-adjusted lenalidomide-cyclophosphamide-prednisone.47 
Careful monitoring of toxicity and prompt administration 
of supportive care such as G-CSF in case of neutropenia is 
important in this group of patients.
Renal impairment
Bortezomib clearance is independent of renal function 
and overcomes the adverse impact of renal dysfunction. 
Importantly, it also improves renal function to a higher degree 
than conventional chemotherapy or IMiD-based regimens. 
This suggests that relapsed/refractory patients presenting 
with renal insufficiency should receive bortezomib-based 
treatment. However, in case of bortezomib-refractory disease 
or intolerance to bortezomib, thalidomide or dose-adjusted 
lenalidomide-based regimens can be considered.85
Lenalidomide is a renally metabolized drug, and with-
out dose adjustments myelosuppression is more frequent 
in patients with renal impairment.86–88 In a subgroup 
analysis of MM-009 and MM-010 studies (starting dose 
of lenalidomide 25 mg for all patients), response and TTP 
was independent of renal function. Improvement of renal 
function was observed in the majority of patients with renal 
impairment. However, patients with severe renal impair-
ment had a shorter OS.87
With dosing of lenalidomide being administered accord-
ing to creatinine clearance (Table 4), toxicity of lenalidomide 
Table  4  Adjustment  of  lenalidomide  dose  in  case  of  renal 
impairment
Creatinine clearance Lenalidomide (days 1–21 of a 28-day cycle)
$50 mL/min 25 mg/day (standard dose)
30–50 mL/min 10 mg/day
#30 mL/min 15 mg/2 days
Dialysis 5 mg/day; on days of dialysis, dose should be 
administered after dialysis
was independent of renal function.89 The response rate, PFS, 
and OS following lenalidomide-dexamethasone were iden-
tical between patients with and without renal impairment, 
and treatment was associated with improvement of renal 
function. However, a retrospective single center study from 
Germany with a starting dose of lenalidomide according to 
renal function showed that TTP following lenalidomide-
dexamethasone was significantly shorter in the case of severe 
renal impairment, probably due to dose interruptions and 
reductions resulting from toxicity.41
Adjusted dose lenalidomide-based therapy can also be 
administered to patients requiring dialysis, which is effec-
tive, but accompanied by a high incidence of neutropenia 
and infections.90
Management of adverse events 
associated with lenalidomide
Neutropenia
Neutropenia increases the risk of bacterial and fungal 
infection, and is a common adverse event of lenalidomide 
treatment. The incidence of grade 3/4 neutropenia in the 
MM-009 and MM-010 studies was 41.2% and 29.5%, 
respectively, in lenalidomide plus dexamethasone-treated 
patients, whereas it was only 4.6% and 2.3%, respectively, 
in the placebo plus dexamethasone group.25,26 The risk of 
developing grade 3/4 neutropenia is higher when lenali-
domide is combined with other chemotherapeutic agents 
such as alkylating drugs (eg, MPR) or doxorubicin (eg, 
RAD). Extensive previous treatment is also an important 
risk factor. Therapy-related toxicities including infections 
may lead to early treatment discontinuations, thereby 
negatively affecting outcomes.91 When patients start with 
lenalidomide-based treatment, the blood counts should be 
monitored biweekly, but in case of pre-existing cytopenia, 
weekly monitoring is recommended. Growth factor sup-
port, and sometimes dose adjustments and dose interrup-
tions, should be considered in case neutropenia develops 
(Table 5). Patients at high risk of developing neutropenia 
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Table 5 Supportive care for the management or prevention of 
adverse events associated with lenalidomide
Averse event Supportive care
Neutropenia G-CSF
Anemia Red cell transfusion; start of erythropoietin†
Thrombocytopenia Platelet transfusion
Diarrhea Loperamide
Rash Limited, localized rash: antihistamines  
and topical steroids
Mild but extensive rash: short course  
of low-dose prednisone
vTE Thromboprophylaxis (aspirin for patients at  
standard risk for vTE and LMWH or adjusted- 
dose warfarin in high-risk patients) is indicated  
when lenalidomide is combined with  
dexamethasone or cytotoxic agents
Note: †Concomitant use of erythropoietin with lenalidomide-based combinations 
may increase risk of vTE.
Abbreviations:  G-CSF,  granulocyte-colony  stimulating  factor;  vTE,  venous 
thromboembolism; LMWH, low molecular weight heparin.
based on patient-, MM-, and treatment-related factors may 
benefit from primary prophylaxis with G-CSF.
venous thromboembolism
Lenalidomide used as a single agent does not increase the 
risk of VTE. However, treatment with lenalidomide plus 
dexamethasone or cytotoxic agents results in a higher inci-
dence of VTE.25,26,48 In the MM-009 and MM-010 trials, the 
incidence of grade 3 and 4 thromboembolic events was 11.4% 
and 14.7%, respectively, in the lenalidomide plus dexametha-
sone group, which was significantly higher compared to 4.6% 
and 3.4%, respectively, in the placebo plus dexamethasone 
group.25,26 Importantly, in both studies thromboprophylaxis 
was not required. Risk factors for thromboembolic events 
associated with lenalidomide-dexamethasone treatment 
include high-dose dexamethasone32,92–94 and concomitant 
erythropoietin administration.92,94–96 A subgroup analysis 
of the MM-009 and MM-010 trials showed an increased 
rate of VTE during lenalidomide-dexamethasone therapy 
in previously thalidomide-exposed patients when compared 
with thalidomide-naïve patients.35 Interestingly, data suggest 
that the frequency of VTE may be markedly reduced when 
bortezomib is combined with IMiD-based regimens with high 
thrombogenic potential, even when no thromboprophylaxis 
was administered.51,97–103
In addition, patient-related factors such as advanced age, 
history of VTE, immobilization, inherited thrombophilic 
disorders, and comorbidities such as diabetes mellitus and 
cardiac disease, contribute to the development of VTE during 
lenalidomide therapy. Patients treated with lenalidomide-
dexamethasone who developed a VTE did not experience 
shorter OS or TTP.104
Importantly, with thalidomide and lenalidomide-based 
combination therapies, prophylactic treatment with aspirin in 
patients at standard risk for VTE and low molecular weight 
heparin, or adjusted dose warfarin for high-risk patients 
reduces the frequency of VTE (Table 5).93,95,96,105,106
Secondary malignancies
There have been recent concerns over the use of lenali-
domide and the risk of developing second primary 
malignancies. There is an increased incidence of second 
primary malignancies in newly diagnosed MM patients 
receiving lenalidomide plus melphalan/prednisone 
(MPR).107,108 In the randomized Phase III, MM-015 study, 
the 3-year rate of invasive primary tumors was 7% in 
patients treated with MPR, 7% in patients treated with 
MPR followed by lenalidomide maintenance (MPR-R), but 
only 3% in the melphalan/prednisone group.108 In addition, 
patients receiving lenalidomide maintenance following 
high-dose therapy with autologous stem cell   rescue 
had a significantly higher incidence of second primary 
cancers.109–112 In the Intergroupe Francophone du Myelome 
trial, the incidence of second primary cancers was 3.1 per 
100 patient-years in the lenalidomide group versus 1.2 per 
100 patient-years in the placebo group.111 In the CALGB 
study, 3.5% and 4.3% of the patients in the lenalidomide 
maintenance group developed new hematologic cancers 
and solid-tumor cancers (excluding nonmelanoma skin 
cancers),   respectively.112 The corresponding numbers are 
0.4% and 2.2% in the placebo group.112
A retrospective pooled analysis of 11 clinical trials of 
lenalidomide-based therapy has addressed this issue in the 
relapsed/refractory setting;113 however, in the absence of 
prospective studies, conclusions regarding the incidence of 
second primary cancers are more difficult to draw. In a pooled 
analysis of 3846 relapsed/refractory MM patients treated with 
lenalidomide as a single agent (7%) or in combination with 
dexamethasone (93%), the incidence rate (events per 100 
patient-years) of invasive second primary malignancies was 
2.08, which is comparable to that expected according to the 
Surveillance, Epidemiology and End Results cancer registry 
(2.1).113 The incidence rates (events per 100 patient-years) 
of second primary malignancies, excluding noninvasive skin 
cancers, in the MM-009 and MM-010 trials was 1.71 for 
lenalidomide plus dexamethasone, and 0.91 for placebo plus 
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dexamethasone. This difference was not statistically signifi-
cant, and it was also consistent with the expected incidence 
of invasive cancer in the general population.113 However, there 
was an increased occurrence of noninvasive skin cancers in 
the lenalidomide plus dexamethasone group compared to the 
dexamethasone only group (incidence rate: 2.40 vs 0.91). 
Although there is an increased incidence of non-invasive 
skin cancers in this patient group, there remains a positive 
risk-benefit profile of lenalidomide plus dexamethasone in 
relapsed/refractory MM.113
Other adverse events
Other common adverse events associated with lenalidomide 
treatment include thrombocytopenia, anemia, rash, and 
diarrhea. These toxicities can be managed with dose 
reductions or interruptions, as well as with the start of 
appropriate supportive care (Table 5).114
Concluding remarks
Lenalidomide plus dexamethasone and other lenalidomide-
based combinations are effective treatment options for 
relapsed/refractory MM patients. Several studies demonstrate 
that continued treatment with lenalidomide is associated 
with improved survival. Appropriate dose adjustments and 
institution of supportive care are therefore very important 
to enable patients to continue treatment with lenalidomide-
based therapies until disease progression.
The introduction of the novel agents, thalidomide, lenali-
domide, and bortezomib,115 and the application of high-dose 
therapy with autologous stem cell rescue have improved the 
survival of MM patients. However, event-free and overall 
survival for patients that are refractory to both an IMiD and 
bortezomib is only 5 and 9 months, respectively,116 indicating 
that new drugs are still needed for continued disease control. 
Novel agents are currently being evaluated in clinical trials, 
and include second generation IMiDs such as pomalidomide, 
and second generation proteasome inhibitors, such as carfil-
zomib, MLN 9708, and marizomib. Drugs belonging to other 
classes, such as histone deacetylase inhibitors, Akt inhibitors, 
mTor inhibitors, and several monoclonal antibodies including 
elotuzumab and daratumumab, hold promise for improving 
the outcome of patients with lenalidomide and bortezomib 
refractory disease.67,117 Incorporation of biomarker assess-
ment (using techniques such as fluorescence in situ hybrid-
ization, gene expression profiling, array based comparative 
genomic hybridization, single nucleotide polymorphism 
array, microRNA array, or high throughput sequencing) in 
future studies in relapsed/refractory MM will help to evaluate 
the risk/benefit profile and tailor individualized therapeutic 
approaches. Altogether, this will hopefully translate to further 
improvement in outcomes for MM patients.
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